Xylocaine is named as an intervention in 9 current clinical trials in our Egypt, Sweden, Canada, Mexico and Israel registers. 7 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Hans Bahlmann (1). The most-studied condition is Other Specified Disorders of Kidney and Ureter.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Other Specified Disorders of Kidney and Ureter | 1 |
| Benign Neoplasm of Ureter | 1 |
| Calculus of Kidney and Ureter | 1 |
| Ureter Cancer | 1 |
| Obesity | 1 |
| Pain, Postoperative | 1 |
| Ehlers-Danlos Syndrome | 1 |
| Anesthesia, Local | 1 |
| Sacroiliac Joint Dysfunction | 1 |
| Sacro-Iliac Spondylosis | 1 |
| Scoliosis | 1 |
| Hip Fracture Surgeries | 1 |
| CAD | 1 |
| Arrhythmia Ventricular | 1 |
| Sevoflurane | 1 |
| Sedation | 1 |
| Awake Fiberoptic Intubation | 1 |
| Difficult Airway | 1 |
| Hand Surgery | 1 |
| Local Infiltration | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Egypt | 4 | 3 |
| Clinical trials in Sweden | 2 | 2 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Mexico | 1 | 1 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
9 current trials in our Egypt, Sweden, Canada, Mexico and Israel registers name Xylocaine as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 9 trials are recruiting: 3 with sites in Egypt, 2 with sites in Sweden, 1 with sites in Mexico and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Hans Bahlmann (1), Göteborg University (1), University of Calgary (1) and University of New Mexico (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Xylocaine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Xylocaine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Xylocaine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.